Epoetin alfa + Standard of Care
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hemostasis, Surgical
Conditions
Hemostasis, Surgical
Trial Timeline
Aug 1, 2006 → Feb 1, 2008
NCT ID
NCT00350519About Epoetin alfa + Standard of Care
Epoetin alfa + Standard of Care is a approved stage product being developed by Johnson & Johnson for Hemostasis, Surgical. The current trial status is terminated. This product is registered under clinical trial identifier NCT00350519. Target conditions include Hemostasis, Surgical.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00350519 | Approved | Terminated |
Competing Products
4 competing products in Hemostasis, Surgical
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| FS VH S/D 500 s-apr, 60-seconds polymerization time + FS VH S/D 500 s-apr, 120-seconds polymerization time | Baxter | Phase 2 | 49 |
| Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) | Baxter | Phase 3 | 74 |
| TISSEEL Lyo | Baxter | Phase 3 | 74 |
| Human thrombin + Bovine thrombin | Grifols | Phase 2 | 49 |